A decade of development has yielded the targeted protein degradation (TPD) field its first drug approval with Arvinas' Veppanu. Alongside the 2026 market resurgence, this clinical achievement is poised to inspire novel strategies and elevate TPD to a major milestone.
Industry momentum is already rebounding, evidenced by $15 billion in upfront transactions involving TPD assets and firms during 2026.
Nonetheless, in the context of 2025's cautious investment climate, delivering sustained positive clinical results remains critical to securing investor trust and pharmaceutical backing. To support this goal, the 9th TPD & Induced Proximity Summit serves as the global focal point for attaining vital clinical validation.
Standing as the largest, most detailed TPD conference highlighting advances from initial discovery through clinical trials, the event helps participants identify optimal novel targets, refine degrader characteristics, secure investment and alliances, and speed pipeline progression into clinical phases.
Bringing together experts from organizations such as Arvinas, Revolution Medicines, Foghorn Therapeutics, BMS, Amgen, C4 Therapeutics, and Neomorph, this comprehensive gathering delivers the research, intelligence, and networking necessary to advance induced proximity programs and redefine treatments in oncology, immunology, and neurodegenerative diseases.
About 9th TPD & Induced Proximity Summit
After a decade of innovation, the TPD field has its first drug approval in the form of Arvinas’ Veppanu. Combined with the recovering market of 2026, this clinical validation will unleash a new wave of innovative approaches and push TPD to a new inflection point. Already, the headwinds are reversing with $15 B worth of upfront deals involving TPD candidates and companies in 2026 alone.
However, following the risk-averse funding environment of 2025, continued positive clinical data is key to regaining investor confidence and pharma interest. That’s why the 9th TPD & Induced Proximity Summit is returning as the globe’s definitive forum to help you gain that ever-important clinical validation. As the world’s largest and most comprehensive TPD conference featuring the latest data from early discovery to clinical development, it is designed to help you discover the best novel targets, optimize your degrader profile, attract funding and partnerships, and accelerate your pipelines to the clinic and beyond.
Uniting leaders from the likes of Arvinas, Revolution Medicines, Foghorn Therapeutics, BMS, Amgen, C4 Therapeutics, Neomorph and more, this end-to-end forum is designed to equip you with the data, insights and connections to advance your own induced proximity pipeline and transform therapeutic strategies across oncology, immunology and neurodegeneration.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.